/Investor DB

Pivotal Life Sciences — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

Avalyn Pharma Incavalynpharma.cominNASDAQ: AVLNSep 2023 · $175M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+9 more

AptiHealthaptihealth.comApr 2023 · $11M

HealthtechSaratoga Springs, US

Daniel T. Pickett III(Executive Officer, Director)Timothy Koehler(Executive Officer)Greg Stephen(Executive Officer)

BoardHolly Benson(Director)Mary Langowski(Director)Peter Dorsman(Director)

Co-investorsClaritas CapitalWhat If VenturesOlive Tree VenturesTakeda VenturesVista Equity Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.